Volume | 321,508 |
|
|||||
News | (1) | ||||||
Day High | 1.84 | Low High |
|||||
Day Low | 1.695 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
GlycoMimetics Inc | GLYC | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.80 | 1.695 | 1.84 | 1.855 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,495 | 321,508 | $ 1.73 | $ 555,345 | - | 1.11 - 3.5299 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:22:53 | 200 | $ 1.73 | USD |
GlycoMimetics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
110.11M | 64.39M | - | 10k | -36.9M | -0.57 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
GlycoMimetics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLYC Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.29 | 2.3577 | 1.695 | 1.90 | 1,081,992 | -0.56 | -24.45% |
1 Month | 3.07 | 3.16 | 1.695 | 2.32 | 746,378 | -1.34 | -43.65% |
3 Months | 3.03 | 3.38 | 1.695 | 2.62 | 455,492 | -1.30 | -42.90% |
6 Months | 1.15 | 3.5299 | 1.11 | 2.57 | 348,055 | 0.58 | 50.43% |
1 Year | 1.41 | 3.5299 | 1.11 | 2.27 | 262,950 | 0.32 | 22.70% |
3 Years | 2.54 | 4.16 | 0.51 | 2.10 | 434,893 | -0.81 | -31.89% |
5 Years | 12.76 | 13.41 | 0.51 | 3.05 | 484,224 | -11.03 | -86.44% |
GlycoMimetics Description
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection. |